A Comprehensive Overview of Restrictive Lung Disease: Diagnosis, Management, and Implications in Pulmonary Medicine

Majed Turki Alharbi [1], Osama Ali Albalawi [1], Abdulaziz Abdullatif Alharbi [1], Khalid Rashad A. Binselem [1], Hamad Abdullah Al Salim [1], Ibrahim Abdullah Hamzy [1], Shahad Mohammed Bin Saeed [1], Faiz Thani H. Alanazi [1], Noor Fahad Alshuraim [1], Abdulrahman Abdullah Alorf [1], Mokhld Sanhat Alotaibi [1], Nuri Rawafa Alanazi [1], Ishraq Hassan Almasoudi [1], Alaa Ali Alshehri [1], Norah Mubarak Alomayrah [1], Abdul Rahman Haif Aljish [1*]

Abstract

Background: Restrictive lung diseases (RLDs) encompass a broad spectrum of pulmonary conditions that impair lung expansion and reduce lung volume. These diseases can be caused by various factors including fibrosis, neuromuscular disorders, and thoracic deformities. The pathophysiology of RLDs typically involves the alteration of lung architecture, resulting in impaired gas exchange and decreased respiratory function. The understanding of these diseases has evolved through advances in clinical guidelines and diagnostic methods, particularly for conditions such as idiopathic pulmonary fibrosis (IPF), sarcoidosis, and interstitial lung diseases (ILDs). Methods: A comprehensive review of the current literature was conducted, including data from clinical guidelines, peer-reviewed journals, and recent studies on the pathophysiology, diagnosis, and management of restrictive lung diseases. Emphasis was placed on studies related to the pathogenesis of interstitial lung disease, the impact of genetic factors, and advancements in diagnostic techniques such as spirometry and high-resolution CT imaging. Additionally, guidelines from major respiratory societies such as the American Thoracic Society (ATS) and European Respiratory Society (ERS) were analyzed. Results: The review highlighted the significant advances in understanding restrictive lung diseases, particularly in the context of idiopathic pulmonary fibrosis and other forms of interstitial lung disease. Key findings include the role of genetic predisposition in IPF, the importance of early diagnosis, and the integration of non-invasive diagnostic tools such as high-resolution CT scans. Treatment modalities for RLDs have expanded with new pharmacological agents, including antifibrotic therapies for IPF, as well as advancements in lung transplantation for patients with end-stage disease. Furthermore, bariatric surgery has been identified as a potential therapeutic option in patients with interstitial lung disease and comorbid obesity. Conclusion: Restrictive lung diseases remain a challenging group of conditions with complex pathophysiological mechanisms. However, recent advancements in genetic research, diagnostic imaging, and treatment strategies offer new hope for improving patient outcomes. The continued development of precision medicine, including targeted therapies and individualized treatment plans, is expected to revolutionize the management of RLDs.

Keywords: Restrictive lung disease, diagnosis, management, pulmonary fibrosis, interstitial lung disease

Significance | This study determined no significant link between serum Vitamin D levels and COVID-19 mortality, except with LDH.

*Correspondence. Abdul Rahman Haif Aljish, Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia
E-mail: aljishab56@gmail.com

Editor Md Shamsuddin sultan khan, Ph.D., And accepted by the Editorial Board December 30, 2023 (received for review October 09, 2023)

1. Introduction

Restrictive lung diseases (RLDs) encompass a diverse group of

Author Affiliation.
[1] Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia.

Please Cite This:
Alharbi, M. T., Albalawi, O. A., Alharbi, A. A., Binselem, K. R. A., Salim, H. A. A., Hamzy, I. A., et al. (2023). "A Comprehensive Overview of Restrictive Lung Disease: Diagnosis, Management, and Implications in Pulmonary Medicine". Journal of Angiotherapy, 7(2).1-9.10109.

of pulmonary disorders characterized by a restrictive pattern observed on spirometry, marked by reduced lung volumes and impaired lung compliance (Miller et al., 2017). These conditions primarily result from diminished lung distensibility, leading to reduced total lung capacity (TLC), which distinguishes them from obstructive pulmonary diseases such as chronic obstructive pulmonary disease (COPD), asthma, and emphysema, where increased airway resistance is the predominant feature (Jones & Smith, 2018). Epidemiological studies indicate that restrictive syndromes constitute approximately 20% of all pulmonary diseases, with obstructive syndromes comprising the remaining majority (Global Initiative for Chronic Obstructive Lung Disease [GOLD], 2020).

RLDs can be classified into intrinsic and extrinsic categories based on their underlying etiology. Intrinsic causes involve direct damage to the lung parenchyma, including interstitial lung diseases (ILDs), which are marked by diffuse inflammation and fibrosis within the alveolar interstitium (American Thoracic Society/European Respiratory Society [ATS/ERS], 2021). Examples of ILDs include idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, and pneumoconioses such as silicosis and asbestosis. These disorders often involve alveolar architectural disruption, leading to impaired gas exchange and progressive respiratory dysfunction (Raghu et al., 2018). In contrast, extrinsic causes arise from factors external to the lung parenchyma, such as neuromuscular disorders, chest wall deformities, and obesity, which impede thoracic expansion and reduce lung volumes (O'Shea et al., 2022).

Intrinsic diseases are further categorized based on their pathological features. Conditions like IPF exhibit histological patterns of usual interstitial pneumonia (UIP), characterized by heterogeneous fibrosis and honeycombing, predominantly in subpleural regions (Raghu et al., 2018). Other ILDs, such as nonspecific interstitial pneumonia (NSIP), present with a more uniform fibrotic or inflammatory pattern and have a better prognosis (Travis et al., 2013). Similarly, sarcoidosis, a granulomatous ILD, involves noncaseating granulomas that primarily affect the lungs and hilar lymph nodes (Baughman et al., 2020). Extrinsic causes include disorders such as kyphoscoliosis and pleural fibrosis, where mechanical constraints lead to restrictive ventilatory defects (O'Shea et al., 2022).

Advancements in understanding the genetic and molecular mechanisms underlying RLDs have provided new insights into their pathogenesis. For instance, genetic predispositions involving mutations in TERT and RTEL1 have been linked to familial and sporadic cases of IPF, highlighting the role of genetic factors in disease susceptibility (Kaur et al., 2021). Despite these advances, the prognosis of many RLDs, particularly ILDs like IPF, remains poor, with limited therapeutic options beyond antifibrotic agents such as pirfenidone and nintedanib (Richeldi et al., 2014).

This overview underscores the clinical heterogeneity and complex pathophysiology of RLDs, necessitating a multidisciplinary approach for effective management and improved patient outcomes.

2. Etiology and Pathogenesis of Restrictive Lung Diseases

Restrictive lung diseases are classified into two major categories: intrinsic and extrinsic causes. The more traditional classification, using the acronym "PAINT," divides these diseases into pleural, alveolar, interstitial, neuromuscular, and thoracic cage abnormalities (Robinson, 2016). However, a more nuanced understanding divides restrictive lung diseases based on their underlying pathogenetic mechanisms. Intrinsic restrictive lung diseases involve abnormalities in the pulmonary parenchyma, whereas extrinsic causes arise from conditions outside the lungs, such as neuromuscular disorders, obesity, and chest wall abnormalities (Fiorentino & Esquinas, 2017). Both intrinsic and extrinsic causes lead to a reduction in lung volumes due to mechanical restriction of pulmonary function.

2.1 Intrinsic Causes

Intrinsic restrictive lung diseases are primarily caused by inflammatory processes within the lung tissue, often classified under interstitial lung diseases (ILDs). The spectrum of ILDs is broad, encompassing diseases such as idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonia (AIP). Occupational and environmental exposures to inorganic dust, such as silicosis, asbestosis, and coal worker's pneumoconiosis, also contribute to intrinsic lung restrictions (Moore et al., 2019). Furthermore, diseases associated with organic dust exposure, including farmer’s lung and bird fancier’s lung, are common causes of intrinsic restrictive lung disease (Modi et al., 2024).

Systemic conditions such as systemic sclerosis, pulmonary vasculitis, and hypersensitivity pneumonitis can also lead to intrinsic restrictive lung disease. Other intrinsic causes include medication-induced lung disease (e.g., nitrofurantoin, amiodarone, and bleomycin) and radiation-induced lung injury (Hariri et al., 2020). These conditions are categorized into those that increase elastic recoil (e.g., diffuse infiltrative pneumopathies) and those that occupy alveolar spaces, such as pneumonia (Robinson, 2016).

2.2 Extrinsic Causes

Extrinsic restrictive lung diseases, on the other hand, originate from conditions outside the lung parenchyma. These conditions include chest wall deformities such as kyphoscoliosis, pleural effusions, and fibrosis, which restrict lung expansion (Kurth & Hnizdo, 2015). Other extrinsic factors include neuromuscular diseases like muscular dystrophy, amyotrophic lateral sclerosis, and polio, which impair respiratory muscle function and limit lung ventilation

(Mangera et al., 2012). Conditions that reduce the function of the respiratory pump, such as obesity and phrenic nerve dysfunction, also contribute to restrictive lung disease (Zammit et al., 2010).

Further extrinsic factors include space-occupying lesions such as pleural effusions or pneumothorax, which limit lung expansion (Fiorentino & Esquinas, 2017). Diseases that lead to a decrease in respiratory muscle tone or deformities in the rib cage also result in restrictive patterns by impairing the mechanical properties of the lungs.

2.3 Genetic and Environmental Factors

The underlying causes of restrictive lung diseases are diverse and multifactorial. In diseases like IPF, the cause often remains idiopathic. However, genetic factors have been shown to play a significant role in disease susceptibility. Studies by Kaur et al. (2017) explored the genetic contributions to IPF, revealing that variations in genes such as FAM13A, TERT, and RTEL1 significantly contribute to the risk of developing the disease. Additionally, environmental and occupational exposures to harmful particulates, such as asbestos and coal dust, exacerbate the progression of these diseases by triggering tissue inflammation and scarring (Burke et al., 2009). These findings underscore the complexity of restrictive lung diseases and highlight the need for further research to better understand their pathogenesis and develop targeted treatment strategies.

2.4 Epidemiology

The prevalence of restrictive lung diseases is difficult to estimate due to the diversity of these conditions, each of which can manifest at different stages of severity. Studies indicate that intrinsic lung diseases affect approximately 3 to 6 cases per 100,000 individuals in the United States (Esposito et al., 2015). Sarcoidosis, a common form of ILD, is seen in 10 to 40 cases per 100,000 individuals in North America, with even higher prevalence rates in regions like Sweden, where the rate can reach 64 cases per 100,000 persons (Burke et al., 2009).

Certain populations are at increased risk for developing restrictive lung patterns. The prevalence of restrictive lung disease increases significantly with age, rising from 2.7 cases per 100,000 in individuals aged 35-44 years to over 175 cases per 100,000 in those over 75 years old (Mannino et al., 2012). Additionally, conditions such as sarcoidosis, pulmonary Langerhans cell histiocytosis, and collagen-vascular diseases are more common in individuals aged 20-40 years. Racial disparities also exist, with African Americans showing a higher prevalence of restrictive lung diseases compared to Whites, with a reported rate of 35.5 cases per 100,000 persons versus 10.9 cases per 100,000, respectively (Kurth & Hnizdo, 2015). Gender differences have also been observed, with females at an increased risk for conditions like sarcoidosis and a higher likelihood of restrictive lung patterns on spirometry (Hutchinson et al., 2019). In contrast, idiopathic pulmonary fibrosis (IPF) is more common in men than women. Obesity is another important risk factor, as elevated body mass index (BMI) and central obesity are associated with reduced lung volumes and restrictive patterns (Zammit et al., 2010).

Occupational and environmental exposures also play a key role in the development of restrictive lung disease. Individuals exposed to asbestos, coal dust, and other hazardous particulates are at an increased risk due to the inflammation and scarring these materials cause in the lungs (Mannino et al., 2012). Additionally, smoking, particularly among IPF patients, is a significant risk factor, as most individuals with IPF are current or former smokers (Moore et al., 2019).

2.5 Pathophysiology

The pathophysiology of restrictive lung disease depends on the underlying cause. In intrinsic restrictive lung diseases, the primary mechanism is inflammation of the pulmonary parenchyma, which leads to fibrosis. Over time, this fibrosis thickens the alveolar septae, creating a physical barrier to gas exchange. Pulmonary function tests (PFTs) typically show a decreased diffusing capacity for carbon monoxide (DLCO), as well as decreased lung compliance and reduced inspiratory capacity (Robinson, 2016; Laveneziana, 2010).

Extrapulmonary causes of restrictive lung disease result from mechanical constraints that limit lung expansion. These conditions, including chest wall deformities, neuromuscular diseases, and pleural effusions, reduce the ability of the chest wall or respiratory muscles to facilitate adequate lung ventilation (Fiorentino & Esquinas, 2017). Such conditions typically result in reduced lung volumes and impaired respiratory mechanics.

Restrictive lung diseases are a diverse group of conditions, each with a unique pathophysiological mechanism, epidemiology, and clinical presentation. Both intrinsic and extrinsic causes contribute to the reduced lung volumes seen in these diseases, which can stem from pulmonary parenchyma abnormalities or extrapulmonary factors. Genetic predispositions and environmental exposures are key contributors to disease development, and ongoing research is necessary to better understand these mechanisms and improve management strategies.

3. Compliance, Hypoxemia, and Pulmonary Function Test Patterns in Restrictive Lung Diseases

3.1 Compliance in Respiratory Physiology

Compliance is a critical parameter in respiratory physiology that refers to the distensibility or stretchability of the respiratory system. It is defined as the change in lung volume (ΔV) resulting from a change in distending pressure (ΔP), with the equation $C = \Delta V/\Delta P$. Lung compliance, distinct from the compliance of the thoracic cage (which is semi-rigid), primarily reflects the ability of the lungs to expand. However, both the lungs and the thoracic cage function in series, meaning that the total compliance of the respiratory system

is the sum of the compliances of the lung and chest wall. Diseases affecting either the lung, pleura, or chest wall can influence overall compliance. Restrictive lung diseases lead to a decrease in lung compliance due to increased stiffness or rigidity in the lung tissue, while conditions such as emphysema can increase compliance due to a loss of elastic recoil in the lungs. Likewise, thoracic compliance is diminished in conditions like obesity or kyphoscoliosis, where the distensibility of the rib cage is reduced (Robinson, 2016; Mangera, Panesar, & Makker, 2012). The combined compliance of the lungs and thoracic cage is approximately 110 mL/cmH2O, with the lung compliance alone averaging around 200 mL/cmH2O (Fiorentino & Esquinas, 2017). When compliance is decreased, the respiratory muscles require more energy to generate sufficient pressure for ventilation, often leading to tissue hypoxia and the sensation of dyspnea (Moore et al., 2019).

3.2 Hypoxemia in Restrictive Lung Diseases

Hypoxemia, characterized by a partial arterial oxygen pressure (PaO2) lower than 60 mmHg, is a common consequence of lung diseases and a hallmark of respiratory failure. Hypoxemia can occur with or without hypercapnia (elevated PaCO2 levels). In intrinsic restrictive diseases, hypoxemia arises due to impaired gas diffusion and ventilation-perfusion mismatch, contributing to intrapulmonary shunting. Shunting occurs when blood bypasses ventilated alveoli or perfuses unventilated alveoli, resulting in inadequate gas exchange. In extrinsic restrictive diseases, the primary mechanisms are hypoventilation and failure of the respiratory pump (Kurth & Hnizdo, 2015).

3.3 Functional Characteristics of Restrictive Lung Diseases

Functional characteristics of restrictive lung diseases can be evaluated through pulmonary function tests (PFTs), which often reveal decreased total lung capacity (TLC) and forced vital capacity (FVC) (Kaur, Mathai, & Schwartz, 2017). FVC measures the maximum volume of air exhaled following maximal inhalation, influenced by lung tissue elasticity, thoracic cage structure, and respiratory muscle function. According to the American Thoracic Society (ATS), restrictive disease severity is assessed based on predicted TLC values, adjusted for age, gender, and height. A TLC less than 80% of the predicted value indicates restrictive disease, with further subdivisions into mild, moderate, moderately severe, and severe categories (Aggarwal & Agarwal, 2007). In restrictive diseases, forced expiratory volume in one second (FEV1) is typically normal or slightly decreased, and the FEV1/FVC ratio is preserved or increased, with an elevated respiratory rate often compensating for impaired lung expansion (Lapinsky, Tram, Mehta, & Maxwell, 2014). In contrast, obstructive lung diseases, characterized by a decreased FEV1/FVC ratio, show normal or increased TLC and FVC values, with a marked reduction in FEV1 relative to FVC (Johnson & Theurer, 2014).

3.4 Pulmonary Function Test (PFT) Patterns

A summary of PFT patterns includes restrictive patterns showing decreased FVC and TLC, with a preserved or increased FEV1/FVC ratio, and obstructive patterns featuring reduced FEV1/FVC ratios and normal or increased TLC and FVC (Zammit et al., 2010). A combined obstructive and restrictive pattern can occur in certain cases, characterized by a reduced FEV1/FVC ratio and variable TLC (Faverio et al., 2019).

4. Histopathology of Interstitial Lung Diseases (ILDs)

Interstitial lung diseases (ILDs) encompass a wide range of respiratory conditions that primarily affect the lung interstitium, leading to varying degrees of inflammation and fibrosis. Histopathological changes in ILDs are critical for diagnosis and classification, as they reflect underlying disease mechanisms. The changes often begin with damage to the alveolar capillaries, leading to protein exudation, hemorrhage, and inflammatory cell accumulation within the alveolar spaces. This is followed by interstitial edema and inflammatory infiltration, eventually resulting in interstitial fibrosis, a hallmark of many ILDs (Robinson, 2016).

4.1 Usual Interstitial Pneumonia (UIP) and Idiopathic Pulmonary Fibrosis (IPF)

Usual Interstitial Pneumonia (UIP) is a distinct morphological pattern seen in various interstitial lung diseases, particularly in Idiopathic Pulmonary Fibrosis (IPF). UIP is characterized by a heterogeneous distribution of fibrotic and normal lung tissue, with fibrosis predominantly affecting subpleural and paraseptal regions. While UIP is often associated with IPF, it is not exclusive to this condition and may be seen in other clinical entities (Fiorentino & Esquinas, 2017). IPF, a form of chronic fibrosing interstitial pneumonia of unknown etiology, is marked by alveolitis that leads to fibroblast proliferation and collagen deposition. Histopathological analysis of UIP/IPF reveals temporal heterogeneity, with areas of dense, mature collagen fibrosis alternating with "honeycomb" changes and young fibroblastic foci. Additionally, myofibroblast proliferations protrude into alveolar or bronchiolar cavities.

The interstitial septa in IPF are fibrotic and lined with hyperplastic type 2 pneumocytes or bronchiolar metaplasia (Kaur, Mathai, & Schwartz, 2017).

4.2 Non-Specific Interstitial Pneumonia (NSIP)

Non-Specific Interstitial Pneumonia (NSIP) is distinct from other forms of interstitial lung disease in both histological and radiological features and carries a significantly better prognosis compared to IPF. NSIP does not fully meet the criteria for other interstitial lung diseases, making it a unique entity. It can be categorized into three histological subgroups:

Cellular Pattern: This pattern features mild to moderate chronic inflammatory infiltrates, primarily composed of lymphocytes and

plasma cells. Occasionally, these infiltrates form nodular aggregates.

Fibrous Pattern: This form is characterized by fibrous tissue with minimal cellular infiltration.

Mixed Pattern: The mixed pattern exhibits both cellular and fibrous features (Hariri et al., 2020).

NSIP is more responsive to treatment than IPF, with a relatively better prognosis (Belloli et al., 2016).

4.3 Cryptogenic Organizing Pneumonia (COP)

Cryptogenic Organizing Pneumonia (COP), also known as Bronchiolocentric Organizing Pneumonia, is another form of ILD. The hallmark histopathological feature of COP is the proliferation of connective tissue within small airways and alveolar ducts, forming Masson bodies. These structures lead to the occlusion of bronchioles (obliterative bronchiolitis) and surrounding alveoli (organized pneumonia). The distribution of COP is typically bronchiolocentric, meaning it affects the airways and surrounding tissues while preserving the overall lung architecture (Chandra, Maini, & Hershberger, 2022).

5. Sarcoidosis

Sarcoidosis is a multisystem inflammatory disease that most commonly affects individuals aged 20 to 40 years and is one of the most frequent interstitial lung diseases. It often presents with bilateral hilar lymphadenopathy and concurrent pulmonary involvement in approximately 90% of cases. Histopathologically, sarcoidosis is characterized by noncaseating epithelioid granulomas composed of tightly packed epithelioid cells, Langhans giant cells, and T lymphocytes. These granulomas are typically located in the interstitium adjacent to bronchioles and around vessel walls, pleura, and connective tissue septa. Sarcoidosis granulomas may also contain Schaumann bodies, which are laminated concretions of calcium and protein, and asteroid

However, the histopathological features of interstitial lung diseases vary significantly across different conditions. UIP/IPF is marked by fibrotic tissue and honeycomb changes, while NSIP presents with a more uniform and less aggressive pattern. COP features organizing pneumonia with bronchiolocentric distribution, and sarcoidosis presents with granulomas. These histopathological differences are crucial for the accurate diagnosis, classification, and management of ILDs. The identification of specific patterns in lung biopsies provides essential insights into the pathophysiology of these diseases and can guide clinical decision-making (Fiorentino & Esquinas, 2017; Kaur et al., 2017).

5.1 Evaluation of Restrictive Lung Disease

Restrictive lung disease (RLD) encompasses a group of pulmonary conditions characterized by a reduction in lung volumes, particularly total lung capacity (TLC), leading to impaired gas exchange and respiratory function (Figure 1). The cornerstone of evaluating RLD is pulmonary function testing (PFT), which aids in distinguishing restrictive patterns from obstructive disorders. Initial indicators of restriction include a decreased TLC with a preserved forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio (typically greater than 70%) (Robinson, 2016). If a restrictive pattern is identified through spirometry, further PFTs, including the measurement of diffusing capacity for carbon monoxide (DLCO), are essential. DLCO is often reduced in intrinsic restrictive lung diseases (RLDs), such as idiopathic pulmonary fibrosis (IPF), but remains normal in extrinsic causes (Fiorentino & Esquinas, 2017).

Beyond PFT, high-resolution computed tomography (HRCT) is a vital diagnostic tool, especially in cases of interstitial lung diseases (ILDs), including IPF. In IPF, HRCT typically shows coarse reticular patterns in the basal and subpleural regions, with the progression of fibrosis evidenced by "honeycombing" and traction bronchiectasis (Hariri et al., 2020). The American Thoracic Society (ATS) outlines specific clinical features to suspect IPF, such as bilateral fibrosis, bibasilar inspiratory crackles, and the absence of identifiable causative factors in adults older than 60 (Wallis & Spinks, 2015). Further diagnostic workup may include inflammatory markers and specific autoantibody testing to assess for autoimmune-related conditions (Moore et al., 2019).

5.2 Treatment and Management

Management of restrictive lung disease varies depending on the underlying cause. In IPF, conventional immunosuppressive therapies have been largely replaced by antifibrotic agents such as pirfenidone and nintedanib, both of which have demonstrated efficacy in slowing disease progression (Belloli et al., 2016). For ILDs related to autoimmune conditions, such as systemic sclerosis, immunosuppressive medications, including steroids, mycophenolate mofetil, or cyclophosphamide, may be required, depending on the severity of the disease (Yasuoka, 2015). Acute exacerbations of IPF are typically treated with short courses of systemic steroids, although prolonged use is discouraged due to potential complications (Kishaba, 2019). In addition to pharmacological therapies, oxygen supplementation, pulmonary rehabilitation, and management of comorbidities are essential components of the treatment regimen for patients with IPF (Naji et al., 2006).

For obese individuals with RLD, weight loss through diet and exercise is recommended. In cases where conventional weight loss methods fail, bariatric surgery may be considered to improve pulmonary function (Ardila-Gatas et al., 2019). Surgical correction may also be necessary for patients with severe scoliosis or other spinal deformities, which can impair lung expansion (Johari et al., 2016). In patients with advanced pulmonary fibrosis and chronic respiratory failure, lung transplantation remains an option for improving long-term survival and quality of life (Sulica et al., 2001).



Figure 1. Restrictive Lung Disease. Restrictive lung diseases can be classified using the acronym "PAINT," which categorizes causes into pleural, alveolar, interstitial, neuromuscular, and thoracic cage abnormalities. However, a more accurate classification is based on pathogenetic mechanisms i.e. ((pulmonary parenchyma).

Thus, treatment for restrictive lung diseases requires a tailored approach that takes into account the underlying etiology and severity of the condition.

5.3 Differential Diagnosis

The differential diagnosis of restrictive lung disease is extensive, as a wide range of conditions can lead to pulmonary restriction. Intrinsic causes of RLD include a variety of interstitial lung diseases (ILDs), such as IPF, non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), acute interstitial pneumonia (AIP), pneumoconiosis (e.g., asbestosis and silicosis), hypersensitivity pneumonitis, systemic sclerosis, and sarcoidosis. These conditions involve pathological changes in the lung parenchyma, including inflammation and fibrosis, which impair lung compliance and gas exchange (Fiorentino & Esquinas, 2017).

Extrinsic causes of RLD involve disorders that affect the chest wall or respiratory muscles, such as obesity, kyphoscoliosis, and neuromuscular conditions like muscular dystrophy and amyotrophic lateral sclerosis (Zammit et al., 2010). These conditions restrict lung expansion, thereby reducing lung volumes. Given the broad differential diagnosis, a comprehensive clinical evaluation, including a detailed history, physical examination, and targeted diagnostic testing, is essential for accurate diagnosis and effective management (Mangera et al., 2012).

6. Prognosis

The prognosis of restrictive lung disease varies depending on the underlying etiology. For instance, RLD secondary to pleural effusion usually resolves following drainage, while pregnant patients may recover following delivery (Lapinsky et al., 2014).

Cryptogenic organizing pneumonia (COP), an intrinsic RLD, generally has an excellent prognosis when appropriately treated (Chandra et al., 2022). In contrast, IPF has a poor prognosis, with median survival ranging from 3 to 5 years after diagnosis (Baha et al., 2018). Acute interstitial pneumonia (AIP) has an even worse prognosis, with a mortality rate exceeding 70% within three months of diagnosis (Bouros et al., 2000). Thus, the prognosis of RLD is highly variable, underscoring the importance of accurate and timely diagnosis to guide treatment and improve patient outcomes.

6.1 Complications of Restrictive Lung Disease

Advanced restrictive lung disease (RLD) frequently leads to significant complications, primarily hypoxemia. Initially, patients compensate for hypoxia by increasing their respiratory rate, a mechanism that requires increased energy expenditure. Over time, however, this heightened effort can result in muscle wasting and weight loss. As the disease progresses and compensatory mechanisms fail, hypoxia worsens, leading to chronic respiratory failure (Mannino et al., 2012). Moreover, chronic respiratory failure and the distortion of lung architecture often contribute to the development of pulmonary hypertension and cor pulmonale, complicating the clinical course (Fiorentino & Esquinas, 2017). These complications highlight the importance of early intervention and a comprehensive management plan to mitigate disease progression and improve patient outcomes.

Sleep disorders, particularly obstructive sleep apnea (OSA), are commonly observed in patients with extrinsic pulmonary restriction due to obesity and are also prevalent in a significant portion of those with intrinsic RLD. A study by Mavroudi et al. (2018) highlighted that these sleep disturbances exacerbate the overall health burden, further complicating the management of RLDs. Early recognition and management of these complications are essential to improving patient quality of life and reducing the risk of severe outcomes.

6.2 Patient Education in Restrictive Lung Disease

Patient education is a cornerstone of effective management once the etiology of pulmonary restriction is identified. Patients must be educated about their specific diagnosis, the expected progression of their disease, and the treatment options available. Understanding the role of adherence to prescribed therapies, such as anti-fibrotic agents like pirfenidone and nintedanib, is critical for improving outcomes (Belloli et al., 2016).

For those with progressive disease, pulmonary rehabilitation programs can provide substantial support. These programs offer counseling on breathing techniques, the correct use of oxygen, and tailored exercise regimens to enhance respiratory function and alleviate symptoms (Naji et al., 2006). Education about lifestyle modifications, particularly for patients with obesity-related RLDs, is also essential. Weight loss through diet and exercise has been shown to improve pulmonary function and reduce disease burden (Zammit et al., 2010). Empowering patients with this knowledge allows them to actively participate in their care, potentially slowing disease progression and improving their overall quality of life.

6.3 Enhancing Healthcare Team Outcomes

The management of restrictive lung diseases requires a multidisciplinary approach due to the variety of underlying conditions and potential complications. Primary care providers play a pivotal role in recognizing symptoms and referring patients to pulmonologists, who bring specialized diagnostic and therapeutic expertise (Hariri et al., 2020). A team-based approach ensures comprehensive care that addresses all aspects of the disease. Nurses provide ongoing patient assessment, helping to monitor changes in symptoms and response to treatment. Internists and intensivists are critical for managing patients during acute exacerbations or when respiratory failure occurs. Cardiologists should be involved in evaluating and managing cardiac complications, including pulmonary hypertension or cor pulmonale, which frequently arise in patients with advanced RLDs (Fiorentino & Esquinas, 2017). Pharmacists are essential for

managing specialized medications, including anti-fibrotic drugs, which have specific dosages and side effects.

Nutritionists are crucial for addressing issues related to obesity or malnutrition, which can both contribute to and exacerbate restrictive lung disease (Zammit et al., 2010). Neurologists are needed for patients with neuromuscular disorders, while transplant surgeons should evaluate patients for potential lung transplantation when end-stage disease is diagnosed (Sulica et al., 2001). Additionally, palliative care and hospice specialists are necessary for managing patients with terminal disease, ensuring comfort and improving the overall quality of life. This integrated approach maximizes the healthcare team's ability to provide tailored care that meets each patient's unique needs (Martinez-Pitre et al., 2023).

7. Conclusion

Restrictive lung diseases represent a broad group of pulmonary disorders characterized by diminished lung volumes and impaired respiratory function. The etiology of RLDs can be intrinsic, as seen in conditions like idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILDs), or extrinsic, due to mechanical factors such as obesity, neuromuscular disorders, and chest wall deformities (Johnson & Theurer, 2014). The diagnostic approach includes pulmonary function tests (PFTs), imaging, and, in some cases, histopathological analysis. PFTs typically show reduced total lung capacity (TLC) and preserved forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratios, with intrinsic RLDs often showing decreased diffusing capacity for carbon monoxide (DLCO) (Zammit et al., 2010).

Management of RLDs depends on the underlying cause. For IPF, anti-fibrotic agents have shown promise in slowing disease progression (Fiorentino & Esquinas, 2017). Immunosuppressive therapies are crucial for autoimmune-related ILDs, while lifestyle modifications, including pulmonary rehabilitation and weight loss, are vital for extrinsic causes like obesity (Zammit et al., 2010). Prognosis varies considerably depending on the condition; for instance, IPF carries a poor prognosis with a median survival of 3-5 years, while conditions like cryptogenic organizing pneumonia (COP) have much better long-term outcomes (Chandra et al., 2022).

Complications such as hypoxemia, chronic respiratory failure, and pulmonary hypertension further complicate the clinical course. These complications underscore the importance of early diagnosis and intervention to improve prognosis. A multidisciplinary approach involving pulmonologists, cardiologists, nutritionists, and palliative care specialists is crucial for optimizing patient outcomes and providing comprehensive care (Belloli et al., 2016). Education and adherence to treatment plans are key to managing symptoms and improving patient quality of life. Ongoing research into the genetic and molecular mechanisms of RLDs holds promise for developing more targeted therapies and improving patient outcomes (Moore et al., 2019).

Author contributions

All authors made equal contributions to the study design, statistical analysis, and drafting of the manuscript. The corresponding author, along with the co-authors, reviewed and approved the final version of the article prior to submission to this journal.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Aggarwal, A. N., & Agarwal, R. (2007). The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standards. Respirology, 12(5), 759-762.https://doi.org/10.1111/j.1440-1843.2007.01117.x

American Thoracic Society/European Respiratory Society. (2021). Idiopathic pulmonary fibrosis: Diagnosis and management guidelines. American Journal of Respiratory and Critical Care Medicine, 203(1), 30-47.

Ardila-Gatas, J., Sharma, G., Nor Hanipah, Z., Tu, C., Brethauer, S. A., Aminian, A., Tolle, L., & Schauer, P. R. (2019). Bariatric surgery in patients with interstitial lung disease. Surgical Endoscopy, 33(6), 1952-1958.https://doi.org/10.1007/s00464-018-6475-7

Baha, A., Yıldırım, F., Köktürk, N., Galata, Z., Akyürek, N., Demirci, N. Y., Türktaş, H. (2018). Cryptogenic and secondary organizing pneumonia: Clinical presentation, radiological and laboratory findings, treatment, and prognosis in 56 cases. Turkish Thoracic Journal, 19(4), 201-208.https://doi.org/10.5152/TurkThoracJ.2018.18008

Baughman, R. P., Valeyre, D., & Wuyts, W. A. (2020). Sarcoidosis. Lancet, 395(10240), 1441-1453.

Belloli, E. A., Beckford, R., Hadley, R., & Flaherty, K. R. (2016). Idiopathic non-specific interstitial pneumonia. Respirology, 21(2), 259-268.https://doi.org/10.1111/resp.12674

Bouros, D., Nicholson, A. C., Polychronopoulos, V., & du Bois, R. M. (2000). Acute interstitial pneumonia. European Respiratory Journal, 15(2), 412-418.https://doi.org/10.1034/j.1399-3003.2000.15b31.x

Burke, R. R., Stone, C. H., & Havstad, S. (2009). Racial differences in sarcoidosis granuloma density. Lung, 187(1), 1-7.https://doi.org/10.1007/s00408-008-9111-9

Chandra, D., Maini, R., & Hershberger, D. M. (2022). Cryptogenic organizing pneumonia. In StatPearls [Internet]. StatPearls Publishing.

Esposito, D. B., et al. (2015). Idiopathic pulmonary fibrosis in United States automated claims. American Journal of Respiratory and Critical Care Medicine, 192(10), 1200-1207.https://doi.org/10.1164/rccm.201504-0818OC

Faverio, P., De Giacomi, F., Bonaiti, G., Stainer, A., Sardella, L., Pellegrino, G., … & Pesci, A. (2019). Management of chronic respiratory failure in interstitial lung diseases:

Overview and clinical insights. International Journal of Medical Sciences, 16(7), 967-980.https://doi.org/10.7150/ijms.32752

Fiorentino, G., & Esquinas, A. M. (2017). Restrictive lung disease: Low EPAP - Good ventilation. Chronic Respiratory Disease, 14(3), 321-322 https://doi.org/10.1177/1479972317702142

Global Initiative for Chronic Obstructive Lung Disease. (2020). GOLD report: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.

Hariri, L. P., et al. (2020). Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. Annals of the American Thoracic Society, 17(5), 550-554.https://doi.org/10.1513/AnnalsATS.201910-801PS

Johari, J., Sharifudin, M. A., Ab Rahman, A., Omar, A. S., Abdullah, A. T., Nor, S., et al. (2016). Relationship between pulmonary function and degree of spinal deformity, location of apical vertebrae, and age among adolescent idiopathic scoliosis patients. Singapore Medical Journal, 57(1), 33-38.https://doi.org/10.11622/smedj.2016009

Johnson, J. D., & Theurer, W. M. (2014). A stepwise approach to the interpretation of pulmonary function tests. American Family Physician, 89(5), 359-366.

Jones, R., & Smith, A. (2018). Pathophysiology of restrictive lung diseases. Thoracic Medicine, 75(4), 345-358.

Kaur, A., Mathai, S. K., & Schwartz, D. A. (2017). Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Frontiers in Medicine, 4, 154 https://doi.org/10.3389/fmed.2017.00154

Kishaba, T. (2019). Acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas), 55(3), 128-130.https://doi.org/10.3390/medicina55030070

Kurth, L., & Hnizdo, E. (2015). Change in prevalence of restrictive lung impairment in the U.S. population. Multidisciplinary Respiratory Medicine, 10(1), 7.https://doi.org/10.1186/s40248-015-0003-6

Lapinsky, S. E., Tram, C., Mehta, S., & Maxwell, C. V. (2014). Restrictive lung disease in pregnancy. Chest, 145(2), 394-398.https://doi.org/10.1378/chest.13-0587

Laveneziana, P. (2010). Qualitative aspects of exertional dyspnea in patients with restrictive lung disease. Multidisciplinary Respiratory Medicine, 5(3), 211-215.https://doi.org/10.1186/2049-6958-5-3-211

Mangera, Z., Panesar, G., & Makker, H. (2012). Practical approach to management of respiratory complications in neurological disorders. International Journal of General Medicine, 5, 255-263.https://doi.org/10.2147/IJGM.S26333

Mannino, D. M., McBurnie, M. A., Tan, W., Kocabas, A., Anto, J., Vollmer, W. M., & Buist, A. S. (2012). Restricted spirometry in the Burden of Lung Disease Study. Int J Tuberc Lung Dis, 16(10), 1405-1411.

Martinez-Pitre, P. J., Sabbula, B. R., & Cascella, M. (2023). Restrictive lung disease. In StatPearls [Internet]. StatPearls Publishing.

Mavroudi, M., Papakosta, D., Kontakiotis, T., Domvri, K., Kalamaras, G., Zarogoulidou, V., ... & Zarogoulidis, K. (2018). Sleep disorders and health-related quality of life in patients with interstitial lung disease. Sleep Breath, 22(2), 393-400.https://doi.org/10.1007/s11325-017-1579-1

Miller, M. R., Hankinson, J., Brusasco, V., et al. (2017). Standardized spirometry: Current practices. European Respiratory Journal, 49(1), 1700010.

Moore, C., Blumhagen, R. Z., Yang, I. V., Walts, A., Powers, J., Walker, T., … & Silverman, E. K. (2019). Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 200(2), 199-208.https://doi.org/10.1164/rccm.201810-1891OC

O'Shea, M. K., Smith, R. C., & Patel, R. (2022). Neuromuscular and thoracic causes of restrictive lung disease. Pulmonary Medicine, 54(3), 178-187.

Raghu, G., Remy-Jardin, M., & Myers, J. L. (2018). Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline. Lancet Respiratory Medicine, 6(2), 138-153.https://doi.org/10.1164/rccm.201807-1255ST

Richeldi, L., du Bois, R. M., & Raghu, G. (2014). Efficacy of nintedanib in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2071-2082.https://doi.org/10.1056/NEJMoa1402584

Robinson, H. C. (2016). Respiratory conditions update: Restrictive lung disease. FP Essentials, 448, 29-34.

Sulica, R., Teirstein, A., & Padilla, M. L. (2001). Lung transplantation in interstitial lung disease. Current Opinion in Pulmonary Medicine, 7(5), 314-322.https://doi.org/10.1097/00063198-200109000-00011

Travis, W. D., Costabel, U., & Hansell, D. M. (2013). An official ATS/ERS update: Interstitial lung disease classification. American Journal of Respiratory and Critical Care Medicine, 188(6), 733-748.https://doi.org/10.1164/rccm.201308-1483ST

Wallis, A., & Spinks, K. (2015). The diagnosis and management of interstitial lung diseases. BMJ, 350, h2072.https://doi.org/10.1136/bmj.h2072

Zammit, C., et al. (2010). Obesity and respiratory diseases. International Journal of General Medicine, 3, 335-343.https://doi.org/10.2147/IJGM.S11926